The Bone Resorption Assessment is a simple urinary test that provides an accurate assessment of the rate of bone turnover in an individual. Whilst the DEXA scan is the gold standard for assessing osteoporosis and osteopenia, these are usually only carried out every three years. The Bone Resorption Assessment allows the therapist to monitor progress of the rate of bone loss to assess the efficacy of a treatment regimen and intervene before significant loss has occured. It examines pyridinium crosslinks and deoxypyridinoline and is useful in identifying current rate of bone loss.
Pyridinium crosslinks are stabilizers of collagen molecules. Bone collagen contains bothpyridinoline (PYD), which is reflective of collagen loss of all types, and its component deoxypyridinoline (DPD), which specifically reflects bone collagen. Presence in the urine of higher than normal amounts of PYD and DPD indicate a rapid rate of bone loss.
Crosslink excretion is greatly increased in patients with osteoporosis and in cases where medications impact on bone health as well as in a number of other conditions. These include Paget's disease, primary hyperparathyroidism, and osteomalacia. Measurement of PYD crosslinks has also proven useful in arthritic diseases, connective tissue disorders, cancer metastasis, and alcoholic bone disease.
As with the majority of our Functional Tests and in accordance with clinical guidelines, a full Initial Nutrition Consultation is required before running this test with a member of our Nutritional Therapy team. The practitioner can then assess your needs and provide guidance on a Nutrition Plan which may include recommendations for Functional Nutrition Tests if these are deemed useful to influence the guidance. A full test interpretation is then provided during a Follow Up Nutrition Consultation with recommendations put in place taking into account your test results alongside your clinical presentation and health goals.